FOCUS ON FCA/QUI TAM AND CLASS ACTION ACTIVITY

What Lies Ahead for Managed Care Organizations with Respect to Opioid Litigation

May 17, 2019 8:30am

Michael P. Abate
Partner
Kaplan Johnson Abate & Bird LLP (Louisville, KY)

Amanda L. Waesch
Partner
Brennan, Manna & Diamond (Akron, OH)

  • Addressing theories of liability implicating managed care organizations in the current opiod litigation
  • Risk management perspective: how are MCOs handling opioid procedures internally?
  • Addressing treatment for addiction not typically covered: How have plans evolved, if at all, as a result of the epidemic?
    • What changes are plans seeing in their policies in relation to opioid therapies and treatments?
  • Exploring the interest in recouping funds from prescribers who are overprescribing
  • Examining the possibility and probability of suing opioid manufacturers
    • Examining potential affirmative claims health plans would be bringing against manufacturers, distributors, and providers